Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

altRX vs Mochi Health

altRX and Mochi Health sell different medications; this is what separates them.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
altRX logo

altRX

6.7
★★★☆☆3.4/5

Best for: semaglutide from $1149/month

Visit altRX →
VS
Mochi Health logo

Mochi Health

6.6
★★★☆☆3.3/5

Best for: coaching bundled into the price rather than sold separately

Visit Mochi Health →

If you are choosing between altRX and Mochi Health, price alone will not settle it. altRX leads our six-part score, 6.7 to 6.6. One of the two has an FDA warning letter on record, covered below.

altRX vs Mochi Health price

altRX publishes $149 a month. Mochi Health does not post a GLP-1 price we can quote, so you would only learn its cost after an intake.

Medications and formats

AltRX lists semaglutide and tirzepatide; Mochi Health does not name its drug.

On format, altRX prices compounded injections and brand-name pens, while Mochi Health posts no priced format.

If you want the FDA-approved brand rather than a compounded version, altRX is the only one of the two with a brand-name price.

Where each one treats patients

altRX does not publish where it ships, and Mochi Health lists 15 states.

Pricing

altRX

Compounded GLP-1 (semaglutide) starting tierCompounded
$149/mo
semaglutide
Compounded GLP-1/GIP (tirzepatide) starting tierCompounded
$249/mo
tirzepatide
Brand-name Ozempic®Brand-name
$1149/mo
semaglutide
Brand-name Mounjaro®Brand-name
$1249/mo
tirzepatide
Brand-name Zepbound®Brand-name
$1249/mo
tirzepatide
Brand-name Wegovy®Brand-name
$1579/mo
semaglutide

Mochi Health

Starting dose (membership $79/mo + medication)Compounded
$139/mo
semaglutide

Membership is $79/mo plus $60/mo for compounded semaglutide. The $39 membership Mochi leads with is a first-month rate for new customers; the standard rate is $79 per month after that. The $60 is a 'starting at' price that varies by dose, the lowest rung rather than a flat rate. $99 is shown struck through beside it.

Starting dose (membership $79/mo + medication)Compounded
$169/mo
tirzepatide

Membership is $79/mo plus $90/mo for compounded tirzepatide. The $39 membership is a first-month promotional rate; the standard rate is $79. The $90 is a 'starting at' price that varies by dose. $199 is shown struck through beside it.

What each price covers

Both prices cover the clinician visit.

altRX's price also covers the medication itself and shipping, which Mochi Health does not claim.

Mochi Health's price also covers coaching, which altRX does not claim.

altRX is silent on lab work and coaching.

Mochi Health is silent on shipping and lab work.

That matters most for the drug: unless Mochi Health confirms otherwise, budget for medication on top of its listed price.

altRX

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

Mochi Health

Covered by the monthly price

Medication

Charged on top

Clinician visits

In the price

Shipping

Not stated

Lab work

Not stated

Coaching

In the price

Where each one scores higher

Overall, altRX scores 6.7 and Mochi Health 6.6 out of 10.

altRX is stronger on value (5.0 vs 3.0), accessibility (5.0 vs 4.4) and support (7.0 vs 4.0).

Mochi Health is stronger on trust & safety (8.5 vs 3.5).

Effectiveness and user experience are within half a point.

How we score

altRX

6.7/10

Overall

Mochi Health

6.6/10

Value25%

5.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

3.5A
vs
B
8.5

Accessibility10%

5.0A
vs
B
4.4

Support10%

7.0A
vs
B
4.0

FDA warning letters

The FDA sent altRX a warning letter dated June 8, 2026 (letter 728236), and it is still open.

Mochi Health has no FDA warning letter on record with us.

Features & Coverage

FeaturealtRXMochi Health
Starting Price$149/moNot published
Features✓8 features3 features
States AvailableNot disclosed15
Compounded✓ Yes✓ Yes
Brand Name✓ Yes—
FSA/HSA Accepted——
FDA Warning Letters1 letter✓None

About altRX

Compounded plans open at $149 for semaglutide and $249 for tirzepatide. Branded medication runs $1,149-$1,579, a figure that already contains the consult and the shipping. Every one of the four FDA-approved brands is stocked, Mounjaro, Ozempic, Wegovy and Zepbound, which no other entry in our directory matches. altRX works in both modalities, holds LegitScript certification, and prints the FDA compounded-medication disclaimer.

Read our full altRX review →

About Mochi Health

Mochi Health is an obesity medicine telehealth seller running aggressively priced compounded GLP-1 programs.

Read our full Mochi Health review →

Pros & Cons

altRX

What we like

  • Tirzepatide costs $1249 a month, close to the $1249 median for brand-name tirzepatide across the sellers we compare
  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes the medication, clinician visits and shipping

Watch-outs

  • Semaglutide costs $1149 a month, 16% above the $990 median for brand-name semaglutide across the sellers we compare
  • Confirm it serves your state before you start the intake
  • Ask which pharmacy fills the prescription before you pay, so you can check its license
  • The FDA has issued altRX a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Mochi Health

What we like

  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes clinician visits and coaching
  • We found no FDA warning letters issued to Mochi Health

Watch-outs

  • Not included in the monthly price: medication
  • Serves only 15 states, so check that yours is one of them
  • Ask which pharmacy fills the prescription before you pay, so you can check its license
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Winner: altRX

altRX wins this one, 6.7 to 6.6, above all for semaglutide from $1149/month. Mochi Health fits better if coaching bundled into the price rather than sold separately is your priority.

Choose altRX if…

You want semaglutide from $1149/month and an opening price near $149 a month.

Choose Mochi Health if…

You want coaching bundled into the price rather than sold separately.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.5

Sesame Care

Oral orforglipron alongside the injectables

8.4

Collective

Flat any-dose pricing, if you can absorb a $199 annual membership on top

8.6

Found

Tirzepatide at $169/month, 37% below the typical price

altRX vs Mochi Health: FAQ

Only altRX publishes a price ($149 a month). Mochi Health quotes after sign-up.
No. altRX lists semaglutide and tirzepatide; Mochi Health lists no named drug.
altRX does not publish where it ships; Mochi Health lists 15 states. Confirm your state before paying.
Both include the clinician visit. Only altRX includes the medication itself and shipping. Only Mochi Health includes coaching.
altRX has an open FDA warning letter from June 8, 2026. Mochi Health has none.
No. Neither altRX nor Mochi Health pays us anything.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.